Charles Markle, MD
Neurology · Mobile, ALNPI 1194774927
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $165,741 of the $211,510 with a category attached, or 78.4%. 60 manufacturers reported payments, led by AbbVie at 30.6% of the total. Reporting peaked in 2019 at $43,116 and has fallen 68.1% since, to $13,733 in 2025. Among neurology clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,194 payments — averaging $96.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$65K
- Lilly USA, LLC$47K
- EMD Serono, Inc.$47K
- Teva Pharmaceuticals USA, Inc.$21K
- Sanofi$9K
- Novartis$3K
- plus $20K from 54 others
What the payments were for
- Consulting fees$7,6254%
- Speaking & faculty fees$165,74178%
- Grants$440%
- Travel & lodging$4,4822%
- Food & beverage$33,39716%
- Education$2210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$211,510 in reported general payments places this provider in the 95th percentile of 255 neurology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 29 | $648,482 |
| Kesimpta PenOfatumumab | 35 | $349,657 |
| VumerityDiroximel Fumarate | 28 | $271,142 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 13 | $249,546 |
| TecfideraDimethyl Fumarate | 24 | $223,248 |
| Austedo XrDeutetrabenazine | 16 | $165,427 |
| MayzentSiponimod | 13 | $124,473 |
| BotoxOnabotulinumtoxina | 95 | $119,873 |
| UbrelvyUbrogepant | 91 | $112,540 |
| ZeposiaOzanimod Hydrochloride | 11 | $100,331 |
| QuliptaAtogepant | 75 | $88,895 |
| NuplazidPimavanserin Tartrate | 17 | $85,719 |
| Nurtec OdtRimegepant Sulfate | 44 | $78,225 |
| Emgality PenGalcanezumab-Gnlm | 74 | $60,983 |
| Aimovig AutoinjectorErenumab-Aooe | 58 | $56,107 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringPrivigen | $185 | $648,48229 claims |
| BiogenVumerity, Tecfidera | $1,134 | $494,39152 claims |
| AbbVieBotox, Ubrelvy, Qulipta | $64,719 | $321,308261 claims |
| Grifols USA, LLCGamunex-C | $210 | $249,54613 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $20,531 | $165,42716 claims |
| NovartisMayzent | $2,722 | $124,47313 claims |
| PfizerNurtec Odt, Eliquis | $760 | $87,05261 claims |
| Acadia Pharmaceuticals IncNuplazid | $991 | $85,71917 claims |
| SK Life Science, Inc.Xcopri | $1,091 | $54,39948 claims |
| Acorda Therapeutics, IncAmpyra | $288 | $51,08312 claims |
| MDD US Operations, LLCGocovri | $521 | $46,23213 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $22 | $33,09317 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 255 neurology providers in Alabama.
Other neurology in Mobile
- Daniel DeesMobile$799K
- Hayden LongMobile$386K
- William KilgoMobile$200K
- Bassam BassamMobile$197K
- Dean NaritokuMobile$160K
- Steve CordinaMobile$69K
- Thomas FosterMobile$51K
- Laura MintoMobile$33K
- Andrew ManleyMobile$33K
- Juan OchoaMobile$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.